Predicting prognosis and immunotherapy response among colorectal cancer patients based on a tumor immune microenvironment-related lncRNA signature.
Predicting prognosis and immunotherapy response among colorectal cancer patients based on a tumor immune microenvironment-related lncRNA signature.
复制标题
DOI：
10.3389/fgene.2022.993714
复制
发表时间：
2022
影响因子：
3.7
通讯作者：
Gao, Feng
中科院分区：
文献类型：
--
作者：
Hu, Chuling;Cai, Du;Zhong, Min-Er;Fan, Dejun;Li, Cheng-Hang;Lv, Min-Yi;Huang, Ze-Ping;Wang, Wei;Wu, Xiao-Jian;Gao, Feng
关键词：
长链非编码RNA（lncRNA）通过调节肿瘤浸润免疫细胞的功能来重塑肿瘤免疫微环境（TIME）。TIME-related lncRNAs（TRLs）对结直肠癌（CRC）预后和免疫治疗反应的影响尚不清楚。为了提供生存和免疫治疗反应预测，开发了CRC时间相关的lncRNA签名（TRLs签名），并通过对97种免疫细胞系、61种CRC细胞系和1807名CRC患者的基因表达谱进行全面分析，探索了相关的潜在调控机制。根据TRLs特征对CRC患者进行分层，在低风险组中观察到生存期延长，而高风险组中的患者具有显著更高的促肿瘤免疫细胞浸润和更高的免疫治疗应答率。通过复杂的TRLs-mRNA调控网络，发现免疫调节途径和免疫治疗反应途径在组间被不同地激活。总之，CRC TRLs签名能够进行预后和免疫治疗反应预测，这可以应用于对患者进行床旁免疫治疗的分层。
Long non-coding RNAs (lncRNAs) remodel the tumor immune microenvironment (TIME) by regulating the functions of tumor-infiltrating immune cells. It remains uncertain the way that TIME-related lncRNAs (TRLs) influence the prognosis and immunotherapy response of colorectal cancer (CRC). Aiming at providing survival and immunotherapy response predictions, a CRC TIME-related lncRNA signature (TRLs signature) was developed and the related potential regulatory mechanisms were explored with a comprehensive analysis on gene expression profiles from 97 immune cell lines, 61 CRC cell lines and 1807 CRC patients. Stratifying CRC patients with the TRLs signature, prolonged survival was observed in the low-risk group, while the patients in the high-risk group had significantly higher pro-tumor immune cells infiltration and higher immunotherapy response rate. Through the complex TRLs-mRNA regulation network, immunoregulation pathways and immunotherapy response pathways were found to be differently activated between the groups. In conclusion, the CRC TRLs signature is capable of making prognosis and immunotherapy response predictions, which may find application in stratifying patients for immunotherapy in the bedside.
登录
查看更多内容
影响因子：
16.6
作者：
Cortes-Ciriano I;Lee S;Park WY;Kim TM;Park PJ
通讯作者：
Park PJ
影响因子：
5.2
作者：
Chen, Min-Shan;Lo, Yuan-Hung;Shroyer, Noah F.
通讯作者：
Shroyer, Noah F.
影响因子：
4
作者：
Huang, Jian-kang;Ma, Ling;Zhou, Rui
通讯作者：
Zhou, Rui
影响因子：
4
作者：
Jiang, Wen;Zhu, Dandan;Zhu, Yu
通讯作者：
Zhu, Yu
影响因子：
3.3
作者：
Laibe, Sophy;Lagarde, Arnaud;Olschwang, Sylviane
通讯作者：
Olschwang, Sylviane